Still don't get how they get SNGX out of Soligenix. A bit of a nitpick from me.
Considering the same basic steroid product is now being compounded and used by transplant centers for the same indication, one would think the trial has a good chance of working.
Doesn't it follow that the commercial upside is limited given this practice as well?
Market Data 
Markets 
AI
